Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1076
- Registration Number
- NCT00005596
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 838
- Registration Number
- NCT00005585
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00015873
- Locations
- 🇮🇹
Ospedale San Gerardo, Monza, Italy
🇳🇱Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
🇬🇧Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002756
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Childhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- Biological: filgrastimProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT00022737
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
- Conditions
- LeukemiaLymphoma
- Interventions
- Biological: dactinomycinBiological: sargramostimRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT00002766
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-01-21
- Target Recruit Count
- 1500
- Registration Number
- NCT00003728
- Locations
- 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷CHR de Besancon - Hopital Saint-Jacques, Besancon, France
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 179
- Registration Number
- NCT00003650
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 1800
- Registration Number
- NCT00003437
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.